(0.14%) 5 476.99 points
(0.07%) 39 139 points
(0.44%) 17 795 points
(-0.19%) $80.68
(-5.04%) $2.62
(-0.91%) $2 309.70
(-0.34%) $28.77
(3.07%) $1 016.70
(0.33%) $0.936
(0.79%) $10.69
(0.50%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform...
Stats | |
---|---|
Dagens volum | 3.17M |
Gjennomsnittsvolum | 3.97M |
Markedsverdi | 154.90M |
EPS | $-0.140 ( Q1 | 2024-05-13 ) |
Neste inntjeningsdato | ( $0.0300 ) 2024-08-01 |
Last Dividend | $12.19 ( 2012-11-09 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.310 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00200 (0.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-18 | Watson W. Mark | Buy | 20 000 | Common Stock |
2024-06-12 | Lee Phillip E | Sell | 2 007 | Common Stock |
2024-06-11 | Wheadon David E. | Buy | 95 400 | Stock Option (right to buy) |
2024-06-11 | Wheadon David E. | Buy | 16 000 | Common Stock |
2024-06-11 | Finney Michael J. | Buy | 16 000 | Common Stock |
INSIDER POWER |
---|
95.03 |
Last 96 transactions |
Buy: 9 843 210 | Sell: 241 812 |
Volum Korrelasjon
Vaxart Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
BHFAP | 0.89 |
CFBK | 0.879 |
IDYA | 0.871 |
BHFAO | 0.863 |
LANDO | 0.859 |
MNDY | 0.854 |
FGEN | 0.843 |
DUOT | 0.842 |
CIBR | 0.835 |
BASE | 0.833 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Vaxart Inc Korrelasjon - Valuta/Råvare
Vaxart Inc Økonomi
Annual | 2023 |
Omsetning: | $7.38M |
Bruttogevinst: | $2.88M (39.02 %) |
EPS: | $-0.570 |
FY | 2023 |
Omsetning: | $7.38M |
Bruttogevinst: | $2.88M (39.02 %) |
EPS: | $-0.570 |
FY | 2022 |
Omsetning: | $107 000 |
Bruttogevinst: | $-3.16M (-2 953.27 %) |
EPS: | $-0.840 |
FY | 2021 |
Omsetning: | $892 000 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.580 |
Financial Reports:
No articles found.
Vaxart Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $12.19 | 2012-11-09 |
Last Dividend | $12.19 | 2012-11-09 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $12.19 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $12.19 | 9.77% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
09 Nov 2012 | $12.19 | 25 Oct 2012 | 26 Oct 2012 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -11.31 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.922 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.211 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.14 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.76 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.894 | 1.500 | 0.590 | 0.885 | [0.2 - 2] |
debtRatioTTM | 0.0792 | -1.500 | 8.68 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -39.48 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.398 | 2.00 | -0.133 | -0.265 | [0 - 30] |
freeCashFlowPerShareTTM | -0.403 | 2.00 | -0.201 | -0.403 | [0 - 20] |
debtEquityRatioTTM | 0.126 | -1.500 | 9.50 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.360 | 1.000 | 7.33 | 7.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | -11.32 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -9.57 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0815 | 0.800 | -2.79 | -2.23 | [0.5 - 2] |
Total Score | -1.968 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.425 | 1.000 | -0.245 | 0 | [1 - 100] |
returnOnEquityTTM | -1.211 | 2.50 | -9.36 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.403 | 2.00 | -0.134 | -0.403 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.398 | 2.00 | -0.133 | -0.265 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0204 | 1.500 | -3.47 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -9.29 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.60 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.